Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 50 to 59 years of age~* No fever on vaccination days~* Must have had chickenpox or lived in an area where the chickenpox virus is prevalent for 30 or more years~* Females of child-bearing potential must use acceptable forms of birth control~Exclusion Criteria:~* Prior history of shingles~* Prior receipt of any chickenpox or shingles vaccine~* Pregnant or breastfeeding~* Received or expect to receive a live virus vaccine (such as measles, mumps, rubella) from 4 weeks before the first visit through the last visit~* Received or expect to receive an inactivated vaccine (such as tetanus or pneumonia) from 7 days before the first visit through the last visit~* Received immunoglobulin or blood products~* Receiving treatment that may weaken the immune system~* Have an immune system disorder

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine (Type: EXPERIMENTAL): Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine A; 4-dose regimen administered \~30 days apart.
- Part 1: Gamma- Irradiated VZV Vaccine A (Type: EXPERIMENTAL): Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered \~30 days apart.
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Participants received a 4-dose placebo regimen administered \~30 days apart.
- Part 2: Gamma- Irradiated VZV Vaccine B (Type: EXPERIMENTAL): Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered \~30 days apart.
- Part 2: Gamma- Irradiated VZV Vaccine C (Type: EXPERIMENTAL): Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered \~30 days apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).